Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form

Pharmacologic inhibition of ROCK2 suppresses amyloid-β production in an Alzheimer's disease mouse model

Academic Article
uri icon
  • Overview
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Herskowitz, J. H.
  • Feng, Yangbo
  • Mattheyses, A. L.
  • Hales, C. M.
  • Higginbotham, L. A.
  • Duong, D. M.
  • Montine, T. J.
  • Troncoso, J. C.
  • Thambisetty, M.
  • Seyfried, N. T.
  • Levey, A. I.
  • Lah, J. J.

publication date

  • December 2013

journal

  • Journal of Neuroscience  Journal

abstract

  • Alzheimer's disease (AD) is the leading cause of dementia and has no cure. Genetic, cell biological, and biochemical studies suggest that reducing amyloid-β (Aβ) production may serve as a rational therapeutic avenue to delay or prevent AD progression. Inhibition of RhoA, a Rho GTPase family member, is proposed to curb Aβ production. However, a barrier to this hypothesis has been the limited understanding of how the principal downstream effectors of RhoA, Rho-associated, coiled-coil containing protein kinase (ROCK) 1 and ROCK2, modulate Aβ generation. Here, we report that ROCK1 knockdown increased endogenous human Aβ production, whereas ROCK2 knockdown decreased Aβ levels. Inhibition of ROCK2 kinase activity, using an isoform-selective small molecule (SR3677), suppressed β-site APP cleaving enzyme 1 (BACE1) enzymatic action and diminished production of Aβ in AD mouse brain. Immunofluorescence and confocal microscopy analyses revealed that SR3677 alters BACE1 endocytic distribution and promotes amyloid precursor protein (APP) traffic to lysosomes. Moreover, SR3677 blocked ROCK2 phosphorylation of APP at threonine 654 (T654); in neurons, T654 was critical for APP processing to Aβ. These observations suggest that ROCK2 inhibition reduces Aβ levels through independent mechanisms. Finally, ROCK2 protein levels were increased in asymptomatic AD, mild cognitive impairment, and AD brains, demonstrating that ROCK2 levels change in the earliest stages of AD and remain elevated throughout disease progression. Collectively, these findings highlight ROCK2 as a mechanism-based therapeutic target to combat Aβ production in AD.

subject areas

  • Alzheimer Disease
  • Amyloid Precursor Protein Secretases
  • Amyloid beta-Peptides
  • Amyloid beta-Protein Precursor
  • Animals
  • Aspartic Acid Endopeptidases
  • Blotting, Western
  • Cell Line
  • Cell Survival
  • Chromatography, High Pressure Liquid
  • DNA
  • Dose-Response Relationship, Drug
  • HEK293 Cells
  • Humans
  • Immunohistochemistry
  • Lentivirus
  • Mice
  • Microscopy, Confocal
  • Plasmids
  • Stereotaxic Techniques
  • Tandem Mass Spectrometry
  • rho-Associated Kinases
scroll to property group menus

Identity

PubMed Central ID

  • PMC3850036

International Standard Serial Number (ISSN)

  • 0270-6474

Digital Object Identifier (DOI)

  • 10.1523/jneurosci.2508-13.2013

PubMed ID

  • 24305806
scroll to property group menus

Additional Document Info

start page

  • 19086

end page

  • 19098

volume

  • 33

issue

  • 49

©2021 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support